Evaluation of the Irinotecan/Bevacizumab Association for Naive Unresectable Glioblastoma (TemAvIr)
Evaluation of the Irinotecan/Bevacizumab Association as Neo-adjuvant and Adjuvant Treatment of Chemoradiation With Temozolomide for Naive Unresectable Glioblastoma. Phase II Randomized Study With Comparison to Chemoradiation With Temozolomide
Sponsor: Association de Neuro-Oncologues d'Expression Francaise
Listed as NCT01022918, this PHASE2 trial focuses on Naive Unresectable Glioblastoma and remains completed. Sponsored by Association de Neuro-Oncologues d'Expression Francaise, it has been updated 6 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2020 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jan 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Association de Neuro-Oncologues d'Expression Francaise
- Centre Georges Francois Leclerc
- Hoffmann-La Roche
- National Cancer Institute, France
- Pfizer
- UNICANCER
For direct contact, visit the study record on ClinicalTrials.gov .